List Title | APhA DrugInfoLine

Focus on Diabetes Care

SORT BY: Most Recent Most Viewed

November 12, 2019

Recent study finds dapagliflozin improves heart failure outcomes regardless of diabetes status

READ

PREVIEW
Use of dapagliflozin (Farxiga—AstraZeneca) in patients with heart failure (HF) and a reduced ejection fraction (EF) decreased the risk of worsening HF or cardiovascular (CV) death regardless of...
September 17, 2019

Some diabetic neuropathy medications are associated with falls in older adults

READ

PREVIEW
Use of tricyclic antidepressants (TCAs) or gabapentinoids increased the risk of falls and fractures in older adults with diabetic peripheral neuropathy (DPN), according to results of an...
August 6, 2019

Dulaglutide improves renal and CV outcomes in patients with type 2 diabetes

READ

PREVIEW
Data from the REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial published in Lancet showed that use of once-weekly dulaglutide (Trulicity—Eli Lilly)...
August 6, 2019

Intensive glycemic control did not result in long-term CV benefits

READ

PREVIEW
The New England Journal of Medicine published a 15-year follow-up from the Veterans Affairs Diabetes Trial (VADT), in which patients were randomized to either intensive or standard...
May 21, 2019

New guideline on management of diabetes in older adults

READ

PREVIEW
The Endocrine Society released a clinical practice guideline on management of diabetes in older adults (≥65 y) that considers overall health and quality of life. The guideline, published in the...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.